Send to

Choose Destination
Ophthalmology. 2019 Apr 6. pii: S0161-6420(18)31322-8. doi: 10.1016/j.ophtha.2019.03.050. [Epub ahead of print]

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.

Author information

Wolstan & Goldberg Eye Associates, Torrance, California. Electronic address:
Ophthalmology Associates, Cornea and LaserVision Institute, St. Louis, Missouri.
Florida Eye Microsurgical Institute, Boynton Beach, Florida.
Sun Pharmaceutical Industries, Ltd., Princeton, New Jersey.
i-Novion, Inc., Randolph, New Jersey.
Virginia Eye Consultants and Eastern Virginia Medical School, Norfolk, Virginia.



To evaluate the safety and efficacy of OTX-101, a novel aqueous nanomicellar formulation of cyclosporine (0.09%), in the treatment of patients with dry eye disease (DED).


A randomized, multicenter, vehicle-controlled, double-masked, phase 3 clinical trial.


Adults (18-90 years of age) with a history and clinical diagnosis of DED, a global symptom score of 40 or more (range, 0-100), and a lissamine green conjunctival staining score of 3 or more and 9 or less (range, 0-12) in at least 1 eye.


Eligible patients entered a run-in period of 14 to 20 days in which all patients administered vehicle twice daily. Patients who remained eligible at the baseline (day 0) visit were randomized in a 1:1 ratio to twice-daily treatment with OTX-101 0.09% or vehicle for 84 days.


Efficacy assessments included signs (unanesthetized Schirmer tear test, corneal and conjunctival staining) and symptoms (global symptom score) of DED. The primary end point was the proportion of eyes with a clinically meaningful improvement (increase of ≥10 mm) in Schirmer test score at day 84. Safety evaluations included adverse events (AEs), visual acuity, and intraocular pressure monitoring, slit-lamp, dilated ophthalmoscopy, and fundus examinations.


A total of 744 patients were randomized and received study medication (371 to OTX-101 0.09% and 373 to vehicle). The primary end point was achieved; a significantly greater percentage of eyes in the OTX-101 0.09% treatment group achieved an increase of 10 mm or more in the Schirmer test score at day 84 (OTX-101 0.09%, 16.6%; vehicle, 9.2%; P < 0.001). Significant improvements relative to vehicle also were observed for corneal (days 28, 56, and 84) and conjunctival (days 56 and 84) staining. The global symptom score was reduced from baseline in both treatment groups by approximately 30%; however, no significant separation between groups was observed. The OTX-101 0.09% formulation was well tolerated. Treatment-emergent AEs were primarily mild in intensity.


Clinically and statistically significant improvements in tear production and ocular surface integrity were observed in patients treated with OTX-101 0.09% for DED.

Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center